NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression

Both drugs demonstrated > 50% response for treating depression. NRX-101 demonstrated a mean 76% reduction in symptoms of akathisia compared to lurasidone that...

Related Keywords

Nabekura ,Yamaguchi ,Japan ,Miami ,Florida ,United States ,France ,Americans ,American ,French ,Japanese ,Jonathan Javitt ,Daniel Javitt ,Source Nrx Pharmaceuticals Inc ,Us National Institutes Of Health ,Lotus ,Exchange Commission ,Therapeutics Inc ,American Society Of Clinical Psychopharmacology ,Specialty Pharmaceutical Company ,Nrx Pharmaceuticals ,Nrxp Nrx Pharmaceuticals ,Company Special Protocol Agreement ,Nasdaq ,Prnewswire Nrx Pharmaceuticals Inc ,Securities Exchange ,Effect Size ,American Society ,Clinical Psychopharmacology ,Key Opinion Leaders ,Special Protocol Agreement ,Barnes Akathisia Rating Scale ,Mixed Model ,Repeated Measures ,Accelerated Approval ,Breakthrough Therapy ,New Drug Application ,Hope Therapeutics ,Fast Track Designation ,Securities Exchange Act ,Securities Act ,Annual Report ,Psychiatric Res ,Nc ,